Penumbra, Inc. (NYSE:PEN) Receives Average Rating of “Hold” from Analysts

Posted by on Jul 8th, 2026

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have earned a consensus rating of “Hold” from the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $360.3333.

A number of analysts have recently commented on PEN shares. Wall Street Zen upgraded Penumbra to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Citigroup decreased their price objective on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a report on Thursday, May 7th. Evercore restated an “outperform” rating and issued a $320.00 price target on shares of Penumbra in a research report on Monday. Finally, Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th.

Get Our Latest Stock Analysis on Penumbra

Institutional Investors Weigh In On Penumbra

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC increased its position in shares of Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 82 shares during the period. CIBC Private Wealth Group LLC raised its stake in Penumbra by 2,700.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock valued at $26,000 after acquiring an additional 81 shares during the last quarter. Motiv8 Investments LLC purchased a new position in Penumbra during the fourth quarter worth about $27,000. Morse Asset Management Inc acquired a new position in Penumbra during the 4th quarter worth approximately $39,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

Penumbra Stock Up 0.1%

Penumbra stock opened at $318.40 on Wednesday. The business’s 50-day moving average price is $321.09 and its 200 day moving average price is $329.75. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.52 billion, a price-to-earnings ratio of 73.36, a price-to-earnings-growth ratio of 1.97 and a beta of 0.70. Penumbra has a 52 week low of $221.26 and a 52 week high of $362.41.

Penumbra (NYSE:PEN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The firm had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. During the same period in the previous year, the business earned $0.83 EPS. Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Penumbra will post 5.04 earnings per share for the current year.

About Penumbra

(Get Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Read More

Analyst Recommendations for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.